Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010;362:2380–8. https://doi.org/10.1056/NEJMoa0909530.

Article  CAS  PubMed  Google Scholar 

Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): An open label, randomised phase 3 trial. Lancet Oncol. 2010;11:121–8. https://doi.org/10.1016/S1470-2045(09)70364-X.

Article  CAS  PubMed  Google Scholar 

Wu YL, Cheng Y, Zhou X, Lee KH, Nakagawa K, Niho S, et al. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): A randomised, open-label, phase 3 trial. Lancet Oncol. 2017;18:1454–66. https://doi.org/10.1016/S1470-2045(17)30608-3.

Article  CAS  PubMed  Google Scholar 

Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 2018;378:113–25. https://doi.org/10.1056/NEJMoa1713137.

Article  CAS  PubMed  Google Scholar 

Sakata Y, Sakata S, Oya Y, Tamiya M, Suzuki H, Shibaki R, et al. Osimertinib as first-line treatment for advanced epidermal growth factor receptor mutation-positive non-small-cell lung cancer in a real-world setting (OSI-FACT). Eur J Cancer. 2021;159:144–53. https://doi.org/10.1016/j.ejca.2021.09.041.

Article  CAS  PubMed  Google Scholar 

Mazieres J, Drilon A, Lusque A, Mhanna L, Cortot AB, Mezquita L, et al. Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the immunotarget registry. Ann Oncol. 2019;30:1321–8. https://doi.org/10.1093/annonc/mdz167.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hastings K, Yu HA, Wei W, Sanchez-Vega F, DeVeaux M, Choi J, et al. EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer. Ann Oncol. 2019;30:1311–20. https://doi.org/10.1093/annonc/mdz141.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lee JB, Ou SI. ATTLAS, IMpower151 and ORIENT-31: Dusting off IMpower150 for post-osimertinib in EGFR-mutated NSCLC? Lung Cancer (Auckl). 2024;15:81–5. https://doi.org/10.2147/LCTT.S460870.

Article  PubMed  PubMed Central  Google Scholar 

Schwartz LH, Litière S, de Vries E, Ford R, Gwyther S, Mandrekar S, et al. RECIST 1.1-update and clarification: from the RECIST committee. Eur J Cancer. 2016;62:132–7. https://doi.org/10.1016/j.ejca.2016.03.081.

Article  PubMed  PubMed Central  Google Scholar 

Morimoto K, Sawada R, Yamada T, Azuma K, Ito K, Goto Y, et al. A real-world analysis of immune checkpoint inhibitor-based therapy after osimertinib treatment in patients with EGFR-mutant NSCLC. JTO Clin Res Rep. 2022;3: 100388. https://doi.org/10.1016/j.jtocrr.2022.100388.

Article  PubMed  PubMed Central  Google Scholar 

Mok T, Nakagawa K, Park K, Ohe Y, Girard N, Kim HR, et al. Nivolumab plus chemotherapy in epidermal growth factor receptor-mutated metastatic non-small-cell lung cancer after disease progression on epidermal growth factor receptor tyrosine kinase inhibitors: Final results of CheckMate 722. J Clin Oncol. 2024;42:1252–64. https://doi.org/10.1200/JCO.23.01017.

Article  CAS  PubMed  Google Scholar 

Yang JC, Lee DH, Lee JS, Fan Y, de Marinis F, Iwama E, et al. Phase III KEYNOTE-789 study of pemetrexed and platinum with or without pembrolizumab for tyrosine kinase inhibitor-Resistant, EGFR-mutant, metastatic nonsquamous non-small cell lung cancer. J Clin Oncol. 2024;42:4029–39. https://doi.org/10.1200/JCO.23.02747.

Article  CAS  PubMed  Google Scholar 

Wu SG, Ho CC, Yang JC, Yu SH, Lin YF, Lin SC, et al. Atezolizumab, bevacizumab, pemetrexed and platinum for EGFR-mutant NSCLC patients after EGFR TKI failure: A phase II study with immune cell profile analysis. Clin Transl Med. 2025;15: e70149. https://doi.org/10.1002/ctm2.70149.

Article  CAS  PubMed  Google Scholar 

Nakagawa K, Garon EB, Seto T, Nishio M, Ponce Aix S, Paz-Ares L, et al. Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019;20:1655–69. https://doi.org/10.1016/S1470-2045(19)30634-5.

Article  CAS  PubMed  Google Scholar 

Saito H, Fukuhara T, Furuya N, Watanabe K, Sugawara S, Iwasawa S, et al. Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): Interim analysis of an open-label, randomised, multicentre, phase 3 trial. Lancet Oncol. 2019;20:625–35. https://doi.org/10.1016/S1470-2045(19)30035-X.

Article  CAS  PubMed  Google Scholar 

Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 2013;48:452–8. https://doi.org/10.1038/bmt.2012.244.

Article  CAS  PubMed  Google Scholar 

Ito T, Nagashima H, Akiyama M, Utsumi Y, Sato H, Chiba S, et al. Treatment with immune checkpoint inhibitors after EGFR-TKIs in EGFR-mutated lung cancer. Thorac Cancer. 2022;13:386–93. https://doi.org/10.1111/1759-7714.14267.

Article  CAS  PubMed  Google Scholar 

Zhou J, Yu X, Hou L, Zhao J, Zhou F, Chu X, et al. Epidermal growth factor receptor tyrosine kinase inhibitor remodels tumor microenvironment by upregulating LAG-3 in advanced non-small-cell lung cancer. Lung Cancer. 2021;153:143–9. https://doi.org/10.1016/j.lungcan.2021.01.010.

Article  CAS  PubMed  Google Scholar 

Qin BD, Jiao XD, Yuan LY, Wu Y, Ling Y, Zang YS. Immunotherapy-based regimens for patients with EGFR-mutated non-small cell lung cancer who progressed on EGFR-TKI therapy. J Immunother Cancer. 2024;12: e008818. https://doi.org/10.1136/jitc-2024-008818.

Article  PubMed  PubMed Central  Google Scholar 

Kawachi H, Fujimoto D, Morimoto T, Ito M, Teraoka S, Sato Y, et al. Clinical characteristics and prognosis of patients with advanced non-small-cell lung cancer who are ineligible for clinical trials. Clin Lung Cancer. 2018;19:e721–34. https://doi.org/10.1016/j.cllc.2018.05.014.

Article  PubMed  Google Scholar 

Le X, Nilsson M, Goldman J, Reck M, Nakagawa K, Kato T, et al. Dual EGFR-VEGF pathway inhibition: a promising strategy for patients with EGFR-mutant NSCLC. J Thorac Oncol. 2021;16:205–15. https://doi.org/10.1016/j.jtho.2020.10.006.

Article  CAS  PubMed  Google Scholar 

Yuan XH, Yang J, Wang XY, Zhang XL, Qin TT, Li K. Association between EGFR/KRAS mutation and expression of VEGFA, VEGFR and VEGFR2 in lung adenocarcinoma. Oncol Lett. 2018;16:2105–12. https://doi.org/10.3892/ol.2018.8901.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Haratake N, Hayashi H, Shimokawa M, Nakano Y, Azuma K, Oki M, et al. Phase III clinical trial for the combination of erlotinib plus ramucirumab compared with osimertinib in previously untreated advanced or recurrent non-small cell lung cancer positive for the L858R mutation of EGFR: REVOL858R (WJOG14420L). Clin Lung Cancer. 2022;23:e257–63. https://doi.org/10.1016/j.cllc.2021.10.007.

Article  CAS  PubMed  Google Scholar 

Zhou Q, Li J, Cang SD, Lin JX, Tu HY, Du Y, et al. FLAIR: a phase II, open label, randomized study of osimertinib plus bevacizumab versus osimertinib in recurrent or metastatic treatment-naïve NSCLC patients harboring EGFR 21L858R mutation. Clin Lung Cancer. 2025;26:152.e1-157.e1. https://doi.org/10.1016/j.cllc.2024.09.002.

Article  CAS  Google Scholar 

Shiraishi Y, Kishimoto J, Sugawara S, Mizutani H, Daga H, Azuma K, et al. Atezolizumab and Platinum Plus pemetrexed with or without bevacizumab for metastatic nonsquamous non-small cell lung cancer: a phase 3 randomized clinical trial. JAMA Oncol. 2024;10:315–24. https://doi.org/10.1001/jamaoncol.2023.5258.

Article  PubMed  Google Scholar 

Watanabe S, Furuya N, Nakamura A, Shiihara J, Nakachi I, Tanaka H, et al. A phase II study of atezolizumab with bevacizumab, carboplatin, and paclitaxel for patients with EGFR-mutated NSCLC after TKI treatment failure (NEJ043 study). Eur J Cancer. 2024;197: 113469. https://doi.org/10.1016/j.ejca.2023.113469.

Article  CAS  PubMed